Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SULF2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SULF2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SULF2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SULF2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SULF2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SULF2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SULF2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SULF2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00600704 | Colorectum | CRC | canonical Wnt signaling pathway | 59/2078 | 303/18723 | 1.15e-05 | 3.74e-04 | 59 |
GO:00301773 | Colorectum | CRC | positive regulation of Wnt signaling pathway | 33/2078 | 140/18723 | 2.01e-05 | 5.90e-04 | 33 |
GO:00226124 | Colorectum | CRC | gland morphogenesis | 29/2078 | 118/18723 | 2.74e-05 | 7.49e-04 | 29 |
GO:00016552 | Colorectum | CRC | urogenital system development | 62/2078 | 338/18723 | 4.67e-05 | 1.10e-03 | 62 |
GO:00720011 | Colorectum | CRC | renal system development | 56/2078 | 302/18723 | 7.85e-05 | 1.63e-03 | 56 |
GO:00018221 | Colorectum | CRC | kidney development | 54/2078 | 293/18723 | 1.23e-04 | 2.40e-03 | 54 |
GO:00030123 | Colorectum | CRC | muscle system process | 74/2078 | 452/18723 | 3.92e-04 | 5.80e-03 | 74 |
GO:00902633 | Colorectum | CRC | positive regulation of canonical Wnt signaling pathway | 24/2078 | 106/18723 | 4.89e-04 | 7.00e-03 | 24 |
GO:00720061 | Colorectum | CRC | nephron development | 29/2078 | 142/18723 | 8.29e-04 | 1.04e-02 | 29 |
GO:00974214 | Colorectum | CRC | liver regeneration | 11/2078 | 35/18723 | 1.02e-03 | 1.20e-02 | 11 |
GO:00506733 | Colorectum | CRC | epithelial cell proliferation | 69/2078 | 437/18723 | 1.61e-03 | 1.69e-02 | 69 |
GO:0060348 | Colorectum | CRC | bone development | 37/2078 | 205/18723 | 1.96e-03 | 1.96e-02 | 37 |
GO:0072576 | Colorectum | CRC | liver morphogenesis | 8/2078 | 23/18723 | 2.40e-03 | 2.29e-02 | 8 |
GO:00328351 | Colorectum | CRC | glomerulus development | 15/2078 | 62/18723 | 2.68e-03 | 2.44e-02 | 15 |
GO:0002062 | Colorectum | CRC | chondrocyte differentiation | 21/2078 | 106/18723 | 5.87e-03 | 4.33e-02 | 21 |
GO:0048706 | Colorectum | CRC | embryonic skeletal system development | 23/2078 | 121/18723 | 6.85e-03 | 4.81e-02 | 23 |
GO:00301118 | Endometrium | AEH | regulation of Wnt signaling pathway | 71/2100 | 328/18723 | 3.31e-08 | 1.87e-06 | 71 |
GO:00506738 | Endometrium | AEH | epithelial cell proliferation | 84/2100 | 437/18723 | 4.88e-07 | 1.94e-05 | 84 |
GO:00160558 | Endometrium | AEH | Wnt signaling pathway | 85/2100 | 444/18723 | 4.99e-07 | 1.97e-05 | 85 |
GO:01987388 | Endometrium | AEH | cell-cell signaling by wnt | 85/2100 | 446/18723 | 6.07e-07 | 2.29e-05 | 85 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SULF2 | SNV | Missense_Mutation | rs367871609 | c.518N>T | p.Thr173Met | p.T173M | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SULF2 | SNV | Missense_Mutation | | c.1203G>C | p.Leu401Phe | p.L401F | Q8IWU5 | protein_coding | tolerated(0.21) | benign(0.035) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SULF2 | SNV | Missense_Mutation | rs149787530 | c.1492G>A | p.Gly498Arg | p.G498R | Q8IWU5 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SULF2 | SNV | Missense_Mutation | rs781507832 | c.1181N>A | p.Arg394Gln | p.R394Q | Q8IWU5 | protein_coding | tolerated(0.08) | benign(0.017) | TCGA-BH-A0HI-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SULF2 | SNV | Missense_Mutation | | c.955N>A | p.Gly319Ser | p.G319S | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | tamoxiphen | SD |
SULF2 | insertion | Frame_Shift_Ins | novel | c.454_455insTCCAGTTTGGGGTTATTACAAATAGCGCTGCTGA | p.Tyr152PhefsTer25 | p.Y152Ffs*25 | Q8IWU5 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SULF2 | insertion | Frame_Shift_Ins | novel | c.511_512insGCCGGGTGTGTTGGCACATGCCTGTGGACCCAGCTACTAGAGAG | p.Asn171SerfsTer24 | p.N171Sfs*24 | Q8IWU5 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SULF2 | SNV | Missense_Mutation | novel | c.502N>T | p.Arg168Cys | p.R168C | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SULF2 | SNV | Missense_Mutation | novel | c.1225N>T | p.Arg409Trp | p.R409W | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SULF2 | SNV | Missense_Mutation | | c.439N>A | p.Glu147Lys | p.E147K | Q8IWU5 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |